McKesson: stocks, financial statements

Disable ads for free
Dividends News
Favorites

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other. The U.S. Pharmaceutical and Specialty Solutions segment distributes pharmaceutical and other healthcare-related products and also provides pharmaceutical solutions to pharmaceutical manufacturers in the United States. The European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers and serves patients and consumers in 13 European countries. The Medical-Surgical Solutions segment focuses on medical-surgical supplies and provides logistics and other services to healthcare providers in the United States. The Other segment comprises on McKesson Canada, McKesson Prescription Technology Solutions and in a joint venture. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

  • MCK Ticker
  • NYSE Exchange
  • 78,000 Employees
2 rated
  • $179.00, $-0.91 (-0.51%) Previous Close
  • 1,162,751 Previous Volume
  • $114.86 / $183.23 52 week low / high
  • -2.31% Percent off 52 week high
  • 2020-12-01 Updated
  • 0.92% Dividend Yield (trailing)
  • 0.94% Dividend Yield (forward)
  • 0 Public float
  • 160,564,425 Outstanding shares
  • 12.97 P/E
  • 28.89 B Market Cap
Disable ads for free

Financial statements — McKesson

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 15 2020 2019 2018 2017 2016 2015
Total Revenue
230B 210B 210B 200B 190B 180B
Cost Of Revenue
220B 200B 200B 190B 180B 170B
Gross Profit
11B 11B 10B 11B 11B 11B
Research and Development
96M 71M 130M 340M 390M 390M
Selling General and Admin
8.3B 7.6B 7.3B 7B 6.7B 7B
Operating Expense
230B 210B 210B 200B 190B 180B
Operating Income
3B 3.1B 2.9B 3.4B 3.9B 3.5B
Other Income Expense Net
-1.9B -2.5B -2.7B 3.5B -680M -870M
EBIT
3B 3.1B 2.9B 3.4B 3.9B 3.5B
Interest Income
250M 260M 280M 310M 350M 370M
Pretax Income
1.1B 610M 240M 6.9B 3.3B 2.7B
Income Tax
18M 360M -53M 1.6B 910M 820M
Minority Interest
220M 220M 230M 83M 52M 67M
Net Income
900M 34M 67M 5.2B 2.3B 1.5B
Net Income Basic
900M 34M 67M 5.2B 2.3B 1.5B
20 ← 15 2020 2019 2018 2017 2016 2015
Current cash
4B 3B 2.7B 3B 4B 5.3B
Short term investments
Receivables
17B 15B 14B 14B 14B 13B
Inventory
17B 17B 16B 15B 15B 14B
Other current assets
1.5B 530M 440M 470M 1.1B 1.1B
Current assets
42B 38B 37B 37B 38B 37B
Long term investments
3.5B 3.7B 5.4B 940M
Property plant equipment
4.3B 2.5B 2.5B 2.3B 2.3B 2B
Goodwill
9.4B 9.4B 11B 11B 9.8B 9.8B
Intangible assets
3.6B 4.1B 4.5B 4.1B 3.5B 3.9B
Other assets
1.9B 1.7B 1.6B 1.7B 1.7B 1.5B
Total assets
61B 60B 60B 61B 57B 54B
Accounts payable
37B 34B 32B 31B 29B 25B
Current long term debt
1.1B 330M 1.1B 1.1B 1.6B 1.5B
Other current liabilities
4B 3.4B 3.4B 3.4B 4.9B 4.8B
Total current liabilities
43B 38B 37B 36B 35B 33B
Long term debt
8B 7.3B 6.8B 7.3B 6.5B 8.2B
Other liabilities
1.5B 1.7B 2.1B 1.2B 1.2B 2.7B
Minority Interest
220M 220M 230M 83M 52M 67M
Total Liabilities
55B 50B 49B 48B 46B 44B
Common stock
160M 190M 200M 210M 230M 230M
Retained earning
13B 12B 13B 13B 8.4B 13B
Treasury stock
430K 500K 500K 660K 750K 730K
Capital surplus
6.7B 6.4B 6.2B 6B 5.8B 7B
Shareholder equity
5.1B 8.1B 9.8B 11B 8.9B 8B
Net tangible assets
-25B -22B -20B -18B -17B -18B
20 ← 15 2020 2019 2018 2017 2016 2015
Net Income
900M 34M 67M 5.2B 2.3B 1.5B
Depreciation
920M 950M 950M 910M 890M 1B
Changes in receivables
-2.3B -530M 190M -53M -1.3B
Changes in inventories
-380M -370M -460M 320M -1.3B -2.1B
Cash change
1B 310M -110M -1.3B -1.3B 1.1B
Cash flow
4.8B 4B 4.3B 4.7B 3.7B 3.1B
Capital expenditures
-510M -560M -580M -560M -680M -550M
Investments
1.5B -510M -940M
Investing activity other
-20M -18M -110M
Total investing cash flows
-580M -1.4B -1.5B -3.8B -1.6B -680M
Dividends paid
-290M -290M -260M -250M -240M -230M
Net borrowings
-680M -16M -950M 390M -1.7B -400M
Other financing cash flows
-300M -360M -300M -18M 5M -41M
Cash flow financing
-3.1B -2.2B -3.1B -2.1B -3.5B -970M
Exchange rate effect
-19M -120M 150M -140M 45M -320M
Disable ads for free
Disable ads for free